Onco Targets Ther. 2016 Sep 22;9:5809-5817. doi: 10.2147/OTT.S107946. eCollection 2016.

Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors.

OncoTargets and therapy

Yetkin Yıldız, Cenk Sokmensuer, Suayib Yalcin

PMID: 27703380 PMCID: PMC5036569 DOI: 10.2147/OTT.S107946

Abstract

BACKGROUND: Met and HER-2 are proto-oncogenes encoding receptor tyrosine kinase c-Met and HER-2, respectively. Hepatocyte growth factor (HGF) is a ligand of c-Met. The frequency of c-Met, HGF, and HER-2 expressions in gastric cancer and their association with other clinicopathological factors have not been fully understood.

PATIENTS AND METHODS: Patients with stage 1-4 disease were analyzed. Expressions of c-Met, HGF, and HER-2 were examined using immunohistochemistry.

RESULTS: A total of 143 patients, 97 males and 46 females, were included. C-Met scores were 3(+) in 31.5%, 2(+) in 27.3%, and 1(+) in 10.5% of the patients. There was no statistically significant difference in age, sex, tumor location, differentiation, Lauren classification, TNM staging, presence of distant metastasis, depth of tumor invasion (T), lymphovascular invasion, and survival between c-Met subgroups. Overall HGF positivity was 20.6%. HER-2 scores were 3(+) in 9.1%, 2(+) in 9.8%, and 1(+) in 16.1% of the patients. HER-2 overexpression was associated with better differentiation, intestinal subtype, and advanced stage. C-Met overexpressions were 84.6% in the HER-2-overexpression-positive group and 56.2% in the HER-2-overexpression-negative group. There were no statistically significant differences in survival between the high c-Met-expression-positive and -negative stage 3 and stage 4 patients and between the HGF-positive and -negative groups. The mean survival was 11.6±6.3 months in the HER-2-overexpression-positive stage 4 group and 11.9±6.8 months in the HER-2-overexpression-negative stage 4 group. There were no statistically significant differences in survival between the two groups.

CONCLUSION: c-Met was not associated with any prognostic factors in gastric cancer. HER-2 was associated with better differentiation, intestinal subtype, advanced stage, and c-Met overexpression.

Keywords: HER-2; HGF; c-Met; clinicopathological features; gastric cancer; prognostic factors

References

1. Science. 1986 Jun 27;232(4758):1644-6 - PubMed
2. Gastrointest Cancer Res. 2009 Jan;3(1):29-32 - PubMed
3. Oncol Rep. 2008 Jun;19(6):1477-83 - PubMed
4. World J Gastroenterol. 2014 Apr 28;20(16):4536-45 - PubMed
5. World J Surg Oncol. 2012 Dec 18;10:274 - PubMed
6. Br J Cancer. 2012 Jul 10;107(2):325-33 - PubMed
7. World J Gastrointest Oncol. 2012 Jul 15;4(7):156-69 - PubMed
8. Int J Cancer. 2012 Jun 15;130(12):2912-21 - PubMed
9. Cancer. 1999 May 1;85(9):1894-902 - PubMed
10. J Egypt Natl Canc Inst. 2007 Jun;19(2):147-57 - PubMed
11. PLoS One. 2013 Nov 04;8(11):e79137 - PubMed
12. Histopathology. 2008 Jun;52(7):797-805 - PubMed
13. Int J Clin Oncol. 2014 Apr;19(2):303-11 - PubMed
14. Anticancer Res. 2010 Nov;30(11):4635-41 - PubMed
15. Cancer Lett. 2005 Jul 8;225(1):1-26 - PubMed
16. Semin Oncol. 2001 Oct;28(5 Suppl 16):115-24 - PubMed
17. Pathol Res Pract. 2013 Aug;209(8):479-85 - PubMed
18. Histopathology. 2001 Feb;38(2):96-104 - PubMed
19. Rev Col Bras Cir. 2009 Apr;36(2):131-4 - PubMed
20. J Gastrointest Oncol. 2012 Sep;3(3):251-61 - PubMed
21. Int J Mol Cell Med. 2013 Fall;2(4):199-203 - PubMed
22. Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1021-7 - PubMed

Publication Types

• Journal Article